MK-2870 Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Conditions: Non-small Cell Lung Cancer (NSCLC) Interventions: Biological: MK-2870; Drug: Docetaxel; Drug: Pemetrexed Sponsors: Merck Sharp& Dohme LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Lung Cancer | Merck | Non-Small Cell Lung Cancer | Research | Taxotere